THE USE OF THE ANTIBIOTIC BACITRACIN IN THE HYDROLYTIC DEGRADATION OF RNA

The subject of the present invention is the use of bacitracin for the hydrolytic degradation of RNA, occurring at guanosine residues, preferably in single-stranded RNA regions, and occurring without the involvement of transition metal ions. According to the invention, it is possible to use bacitraci...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	WRZESINSKI, JAN, WROCLAWSKIE CENTRUM BADAN EIT+ SP. Z O.O, BLASZCZYK, LESZEK, CIESIOLKA, JERZY, SZCZEPANIK, WOJCIECH, NAGAJ, JUSTYNA, JEZOWSKA-BOJCZUK, MALGORZATA, KASPROWICZ, ALEKSANDRA, STOKOWA-SOLTYS, KAMILA
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The subject of the present invention is the use of bacitracin for the hydrolytic degradation of RNA, occurring at guanosine residues, preferably in single-stranded RNA regions, and occurring without the involvement of transition metal ions. According to the invention, it is possible to use bacitracin according to a mechanism dependent on the degradation of undesirable RNA, different than that stipulated to-date. La présente invention concerne l'utilisation de bacitracine pour la dégradation hydrolytique d'ARN, survenant au niveau de résidus guanosine, de préférence dans des régions d'ARN monocaténaire, et survenant sans l'implication d'ions de métaux de transition. Selon l'invention, il est possible d'utiliser la bacitracine selon un mécanisme dépendant de la dégradation d'ARN indésirable, différent de celui stipulé à ce jour.